Is the active ingredient in the medication.
Aripiprazole is used to treat schizophrenia in adults and adolescents aged 13 years and older.
It is also used to treat bipolar I disorder (manic depression) in adults and adolescents aged 10 years and older.
In adults, aripiprazole is also used to treat irritability associated with autism spectrum disorder in individuals aged 6 years and older.
Ariphrenz 30mg Tab (Aripiprazole) is an atypical antipsychotic medication that works by regulating the activity of dopamine and serotonin, neurotransmitters in the brain. It helps to improve thinking, mood, and behavior in people with mental health conditions.
Store aripiprazole at room temperature, away from light and moisture. Keep it out of reach of children and pets.
The dosage of aripiprazole varies depending on the individual's condition, age, and response to treatment.
It is typically taken once daily, with or without food.
Your doctor will determine the right dosage for you.
Serious side effects are possible and may include movement disorders, high blood sugar, and neuroleptic malignant syndrome (a potentially life-threatening condition).
Common side effects of aripiprazole may include headache, nausea, vomiting, dizziness, drowsiness, and weight gain.
Avoid alcohol while taking aripiprazole, as it can increase the risk of side effects.
Aripiprazole may cause drowsiness and dizziness. Avoid driving or operating machinery until you know how it affects you.
Aripiprazole should only be used during pregnancy if the potential benefits outweigh the risks. It is unknown if aripiprazole passes into breast milk. Discuss these risks with your doctor before taking aripiprazole.
Aripiprazole is not approved for use in children under the age of 6 years old (for autism) or 10 years old (for bipolar disorder).
Aripiprazole may be adjusted based on kidney or liver function. It's crucial to inform your doctor about any pre-existing conditions.
https://www.mayoclinic.org/diseases-conditions/schizophrenia/diagnosis-treatment/drc-20354550
https://www.ncbi.nlm.nih.gov/pubmed/19851656
https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-requires-boxed-warning-aripiprazole-ablify-and-generic-versions-neuroleptic
